Autoimmune & immunology · Phase III

Top sponsors

• Takeda 39 programs
• Janssen-Cilag International N.V 26 programs
• Anaxis Pharma 20 programs
• AbbVie 18 programs
• Novartis India 17 programs
• AbbVie Deutschland GmbH 13 programs
• HOFFMANN-LA ROCHE 11 programs
• Eli Lilly and 9 programs
• Chinese Academy of 8 programs
• Bristol-Myers Squibb Australia 7 programs
• PARItec 7 programs
• Pacira Ireland 7 programs

1. -, Rozanolixizumab

   Lacuna Pharma Pty Ltd

   Generalized Myasthenia Gravis

   phase 3 · small molecule · active

   1 trial →

2. -, Rozanolixizumab

   Lacuna Pharma Pty Ltd

   Generalized Myasthenia Gravis

   phase 3 · small molecule · active

   1 trial →

3. 01-13

   Apimeds Pharmaceuticals US

   Osteoarthritis of the Knee

   phase 3 · mab · completed

   1 trial →

4. 1305-0046

   Boehringer Ingelheim

   Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD)

   phase 3 · small molecule · active

   1 trial →

5. 20-01/BetaSal-S

   Alphapharm Pty Ltd

   Chronic stable plaque psoriasis

   phase 3 · other · active

   1 trial →

6. 20190529

   Amgen

   Juvenile psoriatic arthritis

   phase 3 · small molecule · active

   1 trial →

7. 20190531

   Amgen

   Behçet’s disease is a chronic, relapsing, multisystem inflammatory disorder of unknown etiology characterized by 4 major symptoms (oral aphthous ulcers, genital ulcers, skin lesions, and ocular lesions) and occasionally by 5 minor symptoms (arthritis, gastrointestinal ulcers, epididymitis, vascular lesions, and central nervous system [CNS] symptoms) (Cho, 2012). Juvenile idiopathic arthritis is a heterogeneous group of chronic inflammatory disorders that initially presents in children by the age of 16 years. It refers to arthritis of at least 6 weeks duration of unknown etiology that begins in children less than 16 years old. Juvenile idiopathic arthritis has an annual incidence of 2 to 20 cases per 100 000 population and a prevalence of 16 to 150 cases per 100 000 population. It is an autoimmune disorder marked by abnormalities of immune responses (Adelowo, 2010).

   phase 3 · small molecule · active

   1 trial →

8. 230LE301

   Biogen

   Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus

   phase 3 · small molecule · active

   1 trial →

9. 230LE303

   Biogen

   systemic lupus erythematosus

   phase 3 · small molecule · active

   1 trial →

10. 230LE304

    Biogen

    systemic lupus erythematosus

    phase 3 · small molecule · active

    1 trial →

11. 230LE306

    Biogen

    Systemic lupus erythematosus

    phase 3 · small molecule · active

    1 trial →

12. 25 mg Ontamalimab

    Takeda

    Crohn's Disease

    phase 3 · small molecule · completed

    1 trial →

13. 410701BS

    Lacuna Pharma Pty Ltd

    Plaque psoriasis

    phase 3 · small molecule · active

    1 trial →

14. 608

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Axial Spondyloarthritis, Non-Radiographic

    phase 3 · small molecule · active

    1 trial →

15. 608 Q2W

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Plaque Psoriasis Patients

    phase 3 · small molecule · active

    1 trial →

16. 608 Q2W

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Psoriasis

    phase 3 · small molecule · completed

    1 trial →

17. 750 mg Imsidolimab

    Vanda Pharmaceuticals Netherlands B.V.

    Generalized Pustular Psoriasis

    phase 3 · small molecule · completed

    1 trial →

18. 77242113CRD3001

    Janssen-Cilag International N.V.

    Moderately to Severely Active Crohn's Disease

    phase 3 · small molecule · active

    1 trial →

19. 77242113PSA3001

    Janssen-Cilag International N.V.

    Active Psoriatic Arthritis

    phase 3 · small molecule · active

    1 trial →

20. 77242113PSO3001

    Janssen-Cilag International N.V.

    Moderate to Severe Plaque Psoriasis

    phase 3 · small molecule · active

    1 trial →

21. 77242113PSO3002

    Janssen-Cilag International N.V.

    Moderate to Severe Plaque Psoriasis

    phase 3 · small molecule · active

    1 trial →

22. 77242113PSO3003

    Janssen-Cilag International N.V.

    Plaque Psoriasis

    phase 3 · small molecule · active

    1 trial →

23. 77242113PSO3004

    Janssen-Cilag International N.V.

    Moderate to Severe Plaque Psoriasis

    phase 3 · small molecule · active

    1 trial →

24. 77242113PSO3006

    Janssen-Cilag International N.V.

    Moderate to Severe Plaque Psoriasis

    phase 3 · small molecule · active

    1 trial →

25. 80202135SLE3001

    Janssen-Cilag International N.V.

    Systemic Lupus Erythematosus

    phase 3 · small molecule · active

    1 trial →

26. A3921145

    Pfizer Australia Pty Ltd

    Juvenile Idiopathic Arthritis (JIA)

    phase 3 · small molecule · active

    1 trial →

27. A3921210

    Pfizer Australia Pty Ltd

    Ulcerative Colitis (UC)

    phase 3 · small molecule · active

    1 trial →

28. AB-01-004

    Dr Reddy''s Laboratories (Australia) Pty Ltd

    Rheumatoid Arthritis

    phase 3 · small molecule · active

    1 trial →

29. AIN457 150 mg

    Novartis Pharmaceuticals

    Moderate to Severe Chronic Plaque-Type Psoriasis

    phase 3 · small molecule · completed

    1 trial →

30. ALXN1720 Placebo Product, Gefurulimab

    Alexion Europe SAS

    Generalized Myasthenia Gravis with autoantibodies against acetylcholine receptor (AChR)

    phase 3 · small molecule · active

    1 trial →

31. AMZ001 Diclofenac gel

    Amzell

    Osteoarthritis of Knee

    phase 3 · small molecule · completed

    1 trial →

32. APHP200038

    Pari Pharma GmbH

    lupus nephritis

    phase 3 · small molecule · active

    1 trial →

33. APHP230823

    Pari Pharma GmbH

    Adults aged at least 18 years with painful base-of-thumb osteoarthritis

    phase 3 · small molecule · active

    1 trial →

34. APHP240792

    Pari Pharma GmbH

    Septic arthritis

    phase 3 · small molecule · active

    1 trial →

35. APHP240804

    Pari Pharma GmbH

    Adult patients with symptomatic and inflammatory Hand osteoarthritis HOA.

    phase 3 · small molecule · active

    1 trial →

36. APHP240920

    Pari Pharma GmbH

    Cutaneous lupus erythematosus

    phase 3 · small molecule · active

    1 trial →

37. ARGX-113-2008

    argenx

    Generalized Myasthenia Gravis

    phase 3 · small molecule · active

    1 trial →

38. ARGX-113-2308

    argenx

    Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

    phase 3 · small molecule · active

    1 trial →

39. ARGX-113-2315

    argenx

    Ocular Myasthenia Gravis

    phase 3 · small molecule · active

    1 trial →

40. ARQ-151 0.3% cream

    Arcutis Biotherapeutics

    Chronic Plaque Psoriasis

    phase 3 · small molecule · completed

    1 trial →

41. AXS-02

    Axsome Therapeutics

    Osteoarthritis, Knee

    phase 3 · small molecule · active

    1 trial →

42. Adalimumab

    AbbVie

    Juvenile Psoriatic Arthritis

    phase 3 · small molecule · active

    1 trial →

43. Adalimumab

    AbbVie

    Psoriatic Arthritis

    phase 3 · small molecule · completed

    1 trial →

44. Afimkibart

    Hoffmann-La Roche

    Moderately to Severely Active Crohns Disease

    phase 3 · small molecule · active

    1 trial →

45. Alicaforsen

    IONIS PHARMACEUTICALS INC

    Crohn's Disease

    phase 3 · small molecule · completed

    2 trials →

46. Amchafibrin

    Lxo Ireland Designated Activity Company

    Osteoarthritis, Knee

    phase 3 · small molecule · completed

    1 trial →

47. Amifampridine Phosphate

    CATALYST PHARMACEUTICALS, INC.

    Myasthenia Gravis, Generalized

    phase 3 · small molecule · completed

    1 trial →

48. Amifampridine Phosphate

    CATALYST PHARMACEUTICALS, INC.

    Myasthenia Gravis, MuSK

    phase 3 · small molecule · terminated

    1 trial →

Frequently asked questions